Pharma Forecast - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Forecast
A recent reader poll focused on predictions for the industry's future.


Pharmaceutical Technology
Volume 33, Issue 2, pp. 14


Alexis Pellek
For the second year in a row, PharmTech asked readers in an online poll what area of the pharmaceutical industry they think will experience the most change in the upcoming year. Respondents said that for 2009, regulation policy and enforcement would change the most (25%), followed by manufacturing equipment and processes (23%), and outsourcing and consulting services (17%).

These results differ slightly from what PharmTech readers thought about 2008, when outsourcing (33%) was the number 1 pick, followed by regulation (23%) and information technology (15%). As it turned out, outsourcing was a big topic in 2008. Most notably, there was Baxter's January recall of heparin products and the later discovery that the contaminated active ingredient came from a supplier in China. Later in the year, news arose of the negative impact that last year's economic meltdown had on the third-quarter reports of contract research and manufacturing organizations.

For 2009, readers seem to expect the most news and change in the area of regulation. As the Obama administration works with new staff at FDA, we might see the agency take on topics such as increased oversight of direct-to-consumer advertising, more implementation of quality systems, the development of a regulatory pathway for follow-on biologics, and an emphasis on foreign inspections.

To cast your vote in our biweekly polls and to see the results of past questions, visit our poll archive at http://PharmTech.com/polls.

Alexis Pellek is an assistant editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here